The ethics of non-inferiority trials

The Lancet

Volumn 371, Issue 9616, 2008, Pages 895-

  Nunn, Andrew J ^a   Meredith, Sarah K ^a   Spigelman, Melvin K ^b   Ginsberg, Ann M ^b   Gillespie, Stephen H ^c  

^a MRC CLINICAL TRIALS UNIT   (United Kingdom)

^b GLOBAL ALLIANCE FOR TB DRUG DEVELOPMENT   (United States)

^c ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

TUBERCULOSTATIC AGENT;

CLINICAL EFFECTIVENESS; CLINICAL RESEARCH; CLINICAL TRIAL; DRUG SENSITIVITY; HUMAN; LETTER; MEDICAL ETHICS; PRIORITY JOURNAL; TREATMENT DURATION; TUBERCULOSIS;

EID: 40649102179     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(08)60404-3     Document Type: Letter

References (3)

1. S Garattini V Bertele' Non-inferiority trials are unethical because they disregard patients' interests Lancet 370 2007 1875 1877
2. W Fox GA Ellard DA Mitchison Studies on the treatment of tuberculosis undertaken by the British Medical Research Council Tuberculosis Units, 1946–1986, with relevant subsequent publications Int J Tuberc Lung Dis 3 1999 S231 S279
3. A Jindani AJ Nunn DA Enarson Two 8-month regimens of chemotherapy for treatment of newly diagnosed pulmonary tuberculosis: international multicentre randomised trial Lancet 364 2004 1244 1251